Table S1. Time-to-Event Composite Outcomes Using the MDRD Equation to Calculate eGFR.

	Placebo (n = 109)	Ramipril (n = 103)	Hazard Ratio (95% CI)
Total follow-up, months	41.8	41.4	
Composite of:			
Doubling of serum creatinine	9	3	
Return to dialysis	6	3	
Repeat transplant	0	0	
Death	4	8	
Total[a]	19	14	0.76 (0.38–1.51)
Composite of:			
≥40% eGFR decline	17	9	
Return to dialysis	6	2	
Repeat transplant	0	0	
Death	4	7	
Total[a]	27	18	0.66 (0.36–1.21)
Composite of:			
≥30% eGFR decline	28	20	
Return to dialysis	5	1	
Repeat transplant	0	0	
Death	1	7	
Total[a]	34	28	0.85 (0.51–1.40)
Composite of:			
≥20% eGFR decline	45	43	
Return to dialysis	4	1	
Repeat transplant	0	0	
Death	1	5	
Total[a]	50	49	1.05 (0.71–1.55)

eGFR, estimated glomerular filtration rate.

[a]All events were time to first occurrence of any component within a particular composite. eGFR was calculated using the MDRD equation.[11]

Table S2. Total Number of Trial Participants Experiencing Any Graft Function Surrogate Endpoint Using the MDRD Equation.

	Placebo (n = 109)	Ramipril (n = 103)	Hazard Ratio (95% CI)
Doubling of serum creatinine	9 (8.2%)	5 (4.9%)	0.59 (0.20–1.77)
eGFR Decline:			
≥40%	18 (17%)	10 (9.7%)	0.52 (0.23–1.16)
≥30%	29 (27%)	21 (20%)	0.75 (0.43–1.31)
≥20%	46 (42%)	44 (43%)	1.02 (0.67–1.54)

eGFR, estimated glomerular filtration rate. eGFR was calculated using the MDRD equation.[11] Data are n (%) of trial participants.